Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy
. Int J Radiat Oncol Biol Phys 2002;52:310-5.
Early complications of high-dose-rate brachytherapy
in soft tissue sarcoma--a comparison with traditional external-beam radiotherapy.
Locally recurrent prostate cancer after high-dose-rate brachytherapy
: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors.
Manfredi et al., "Non-melanoma skin cancer treated with high-dose-rate brachytherapy
and Valencia applicator in elderly patients: a retrospective case series," Journal of Contemporary Brachytherapy, vol.
Treatment of keloids by high-dose-rate brachytherapy
: A seven-year study.
Bryant, "Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy
boost for localised prostate cancer," Radiotherapy and Oncology, vol.
The dosimetric impact of vaginal balloonpacking on intracavitary high-dose-rate brachytherapy
for gynecological cancer.
This deal also includes four high-dose-rate brachytherapy
afterloaders and Oncentra Brachy treatment planning; MOSAIQ Oncology Information System ; Active Breathing Coordinator units; as well as service for the hardware and software.
Single-fraction high-dose-rate brachytherapy
and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: Analysis of short- and medium-term toxicity and quality of life.
It was reported yesterday that the solution allows clinicians to plan and perform high-dose-rate brachytherapy
treatments for prostate cancer, using real-time ultrasound guidance.
We audited the analgesic, anti-emetic and anti-spasmodic drug usage of patients undergoing high-dose-rate brachytherapy
for prostate cancer at the Royal Prince Alfred Hospital.
In the frail elderly patient with superficial lesions in the lower third of the rectum endocavity radiation with orthovoltage applicators or high-dose-rate brachytherapy
give equivalent results to local excision (96% for T1 tumours, 86% for T2).